S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

Area of Science:

• Pharmacology
• Teratology
• Public Health

Background:

• Thalidomide, approved for erythema nodosum leprosum, poses significant teratogenic risks.
• Previous drug safety programs (e.g., isotretinoin, clozapine) provide a basis for risk management.
• A robust system is needed to balance thalidomide's benefits with its potential for severe harm.

Purpose of the Study:

• To detail the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) program.
• To outline the strategies employed by S.T.E.P.S. to prevent fetal exposure to thalidomide.
• To evaluate the S.T.E.P.S. program's potential as a model for managing high-risk medications.

Main Methods:

• Implementing a three-pronged approach: controlling drug access, educating stakeholders, and monitoring compliance.
• Mandatory registration and agreement to protocols for prescribers and pharmacies.
• Patient education on risks, contraception, and regular pregnancy testing; confidential compliance surveys.

Main Results:

• The S.T.E.P.S. program establishes strict controls on thalidomide prescribing, dispensing, and patient use.
• Stakeholder education and rigorous monitoring are key components of the safety protocol.
• The program aims to minimize teratogenic events through controlled access and patient engagement.

Conclusions:

• The S.T.E.P.S. program effectively manages the risks associated with thalidomide therapy.
• Continuous monitoring and program modification ensure ongoing effectiveness.
• S.T.E.P.S. serves as a potential model for managing other high-benefit, high-risk drugs.